CLINICAL TRIALS PROFILE FOR BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Brevibloc Double Strength In Plastic Container
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01114971 ↗ | Labetalol and Esmolol: Vital Signs and Post Operative Pain Management | Completed | Cedars-Sinai Medical Center | Phase 4 | 2009-09-03 | This study proposes to investigate the effects of labetalol or esmolol on managing the vital signs (like blood pressure and heart rate) during surgery, on pain management, and on the later recovery after surgery. It will also assess the cost-effectiveness of Labetalol and esmolol for outpatient surgery. |
| NCT01179113 ↗ | Esmolol Infusion During Laminectomy: Effect on Quality of Recovery | Terminated | Cedars-Sinai Medical Center | Phase 4 | 2011-06-01 | The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication. |
| NCT01208402 ↗ | Esmolol for Treatment of Perioperative Tachycardia | Terminated | Baxter Healthcare Corporation | Phase 3 | 2010-09-01 | The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery. |
| NCT01208402 ↗ | Esmolol for Treatment of Perioperative Tachycardia | Terminated | Duke University | Phase 3 | 2010-09-01 | The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and immediately after surgery. |
| NCT01232400 ↗ | Study to Evaluate Esmolol (Brevibloc) to Manage Cardiac Function in Patients With Subarachnoid Hemorrhage | Withdrawn | University of Michigan | N/A | 2014-07-01 | The purpose of this study is to evaluate the clinical effect of esmolol treatment on cardiac function and electrophysiology; to assess the effects of esmolol treatment on serum adrenergic and cardiac biomarkers; to explore the safety of esmolol treatment shortly after subarachnoid hemorrhage (SAH). Patients will be followed for a maximum of 1 month after the index SAH. The primary outcome will be change in systolic function - ejection fraction by Simpson's rule (baseline versus Day 7 +/- 2 after SAH). |
| NCT01343329 ↗ | Controlling Hyperadrenergic Activity in Neurologic Injury | Withdrawn | Johns Hopkins University | Phase 1/Phase 2 | 2011-07-01 | Traumatic brain injury (TBI) is frequently associated with a hyperadrenergic state accompanied by elevated levels of plasma catecholamines. In its more severe presentation, the hyperadrenergic state presents as dysautonomia, which is characterized by paroxysmal alteration in vital signs, including tachycardia. The investigators hypothesize that intravenous (IV) esmolol is as effective at controlling heart rate in hyperadrenergic states as oral propranolol, which is the standard of care. Our primary endpoint is efficacy of IV esmolol vs a PRN regimen of intermittent B-blockade in controlling heart rate below a pre-specified level (< 100 bpm) after Traumatic Brain Injury (TBI) or hemorrhagic neurologic injury. Heart rates will be recorded continuously as well as hourly. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Brevibloc Double Strength In Plastic Container
Condition Name
Clinical Trial Locations for Brevibloc Double Strength In Plastic Container
Trials by Country
Clinical Trial Progress for Brevibloc Double Strength In Plastic Container
Clinical Trial Phase
Clinical Trial Sponsors for Brevibloc Double Strength In Plastic Container
Sponsor Name
